Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society.
J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692.
Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia.
Vilar L, Vilar CF, Lyra R, Freitas MDC.
Neuroendocrinology. 2019;109(1):7-19. doi: 10.1159/000499694. Epub 2019 Mar 20.
Hyperprolactinemia: pathophysiology and therapeutic approach.
Capozzi A, Scambia G, Pontecorvi A, Lello S.
Gynecol Endocrinol. 2015 Jul;31(7):506-10. doi: 10.3109/09513590.2015.1017810. Epub 2015 Jul 6.
Hyperprolactinemia and insulin resistance.
Gierach M, Bruska-Sikorska M, Rojek M, Junik R.
Endokrynol Pol. 2022;73(6):959-967. doi: 10.5603/EP.a2022.0075.
Hyperprolactinemia.
Biller BM.
Int J Fertil Womens Med. 1999 Mar-Apr;44(2):74-7.
Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.
Rusgis MM, Alabbasi AY, Nelson LA.
Am J Health Syst Pharm. 2021 May 6;78(10):862-871. doi: 10.1093/ajhp/zxab065.
Hyperprolactinemia in women: diagnostic approach.
Glezer A, Garmes HM, Kasuki L, Martins M, Elias PCL, Nogueira VDSN, Rosa-E-Silva ACJS, Maciel GAR, Benetti-Pinto CL, Nácul AP.
Rev Bras Ginecol Obstet. 2024 Apr 25;46:e-FPS04. doi: 10.61622/rbgo/2024FPS04. eCollection 2024.
Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management.
González-Rodríguez A, Labad J, Seeman MV.
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109941. doi: 10.1016/j.pnpbp.2020.109941. Epub 2020 Mar 31.
Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach.
Milano W, Colletti C, Capasso A.
Endocr Metab Immune Disord Drug Targets. 2017;17(1):38-55. doi: 10.2174/1871530317666170424102332.
Hyperprolactinemia associated with psychiatric disorders.
Rizzo LFL, Mana DL, Serra HA, Danilowicz K.
Medicina (B Aires). 2020;80(6):670-680.
